Choreo LLC Boosts Stake in Hologic, Inc. (NASDAQ:HOLX)

Choreo LLC increased its position in Hologic, Inc. (NASDAQ:HOLX) by 14.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,646 shares of the medical equipment provider’s stock after purchasing an additional 825 shares during the quarter. Choreo LLC’s holdings in Hologic were worth $480,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Wolff Wiese Magana LLC purchased a new position in Hologic during the third quarter valued at $25,000. General Partner Inc. bought a new position in shares of Hologic in the 4th quarter worth about $26,000. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Cromwell Holdings LLC boosted its stake in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares in the last quarter. Finally, Covestor Ltd grew its holdings in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Royal Bank of Canada dropped their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average target price of $85.77.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.88% of the company’s stock.

Hologic Stock Performance

HOLX stock opened at $64.47 on Wednesday. The company has a market cap of $14.55 billion, a P/E ratio of 20.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 3.03. Hologic, Inc. has a 1 year low of $63.62 and a 1 year high of $84.67. The stock’s fifty day moving average price is $71.80 and its 200-day moving average price is $77.57.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.